Labcorp (NYSE:LH) Price Target Raised to $395.00

Labcorp (NYSE:LH) had its price target upped by Truist Financial from $365.00 to $395.00 in a research note published on Thursday,Benzinga reports. They currently have a buy rating on the medical research company’s stock.

Other equities analysts have also issued research reports about the stock. Weiss Ratings upgraded shares of Labcorp from a “buy (b+)” rating to a “buy (a-)” rating in a report on Wednesday, October 21st. Mizuho set a $355.00 price target on shares of Labcorp in a research report on Monday, August 10th. UBS Group increased their price target on Labcorp from $380.00 to $420.00 and gave the stock a “buy” rating in a report on Thursday. Leerink Partners set a $410.00 price objective on Labcorp in a research report on Wednesday. Finally, Piper Sandler boosted their price objective on Labcorp from $300.00 to $309.00 and gave the company a “neutral” rating in a research note on Tuesday, August 4th. One equities research analyst has rated the stock with a Strong Buy rating, seven have assigned a Buy rating and three have issued a Hold rating to the stock. According to data from MarketBeat, the company currently has an average rating of “Moderate Buy” and an average target price of $365.67.

Labcorp Stock Performance

NYSE:LH opened at $361.96 on Thursday. The company has a market capitalization of $29.35 billion, a PE ratio of 29.69, a P/E/G ratio of 2.05 and a beta of 0.87. The company has a 50 day simple moving average of $323.23 and a two-hundred day simple moving average of $287.61. The company has a debt-to-equity ratio of 0.60, a quick ratio of 1.53 and a current ratio of 1.41. Labcorp has a fifty-two week low of $244.52 and a fifty-two week high of $371.00.

Labcorp (NYSE:LH) last released its quarterly earnings results on Wednesday, October 28th. The medical research company reported $4.78 earnings per share (EPS) for the quarter, topping the consensus estimate of $4.64 by $0.14. The firm had revenue of $3.81 billion during the quarter, compared to analyst estimates of $3.76 billion. Labcorp had a net margin of 6.88% and a return on equity of 17.13%. The company’s revenue was up 6.9% compared to the same quarter last year. During the same quarter last year, the business earned $4.18 EPS. Research analysts anticipate that Labcorp will post 18.48 earnings per share for the current year.

Labcorp Announces Dividend

The company also recently declared a quarterly dividend, which will be paid on Friday, December 11th. Shareholders of record on Tuesday, November 24th will be issued a $0.72 dividend. The ex-dividend date is Tuesday, November 24th. This represents a $2.88 annualized dividend and a yield of 0.8%. Labcorp’s dividend payout ratio is presently 23.63%.

Insider Buying and Selling at Labcorp

In related news, Director Kerrii B. Anderson sold 3,000 shares of the stock in a transaction on Monday, August 17th. The stock was sold at an average price of $318.02, for a total value of $954,060.00. Following the transaction, the director directly owned 6,563 shares in the company, valued at $2,087,165.26. This trade represents a 31.37% decrease in their position. The sale was disclosed in a document filed with the Securities & Exchange Commission, which is available at this link. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Also, CEO Adam H. Schechter sold 4,669 shares of the stock in a transaction on Tuesday, August 11th. The stock was sold at an average price of $320.37, for a total value of $1,495,807.53. Following the completion of the transaction, the chief executive officer owned 102,565 shares in the company, valued at approximately $32,858,749.05. This represents a 4.35% decrease in their ownership of the stock. The disclosure for this sale is available in the SEC filing. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan. Over the last quarter, insiders sold 8,593 shares of company stock valued at $2,733,295. Company insiders own 0.84% of the company’s stock.

Institutional Trading of Labcorp

A number of hedge funds and other institutional investors have recently bought and sold shares of the business. Allied Private Wealth LLC purchased a new stake in Labcorp in the 2nd quarter valued at about $33,000. Cedar Mountain Advisors LLC lifted its position in shares of Labcorp by 786.7% during the 1st quarter. Cedar Mountain Advisors LLC now owns 133 shares of the medical research company’s stock worth $35,000 after buying an additional 118 shares in the last quarter. William Mack & Associates Inc. bought a new position in shares of Labcorp during the 3rd quarter worth approximately $42,000. Pathway Financial Advisers LLC purchased a new position in shares of Labcorp in the 3rd quarter worth approximately $43,000. Finally, Jones Financial Companies Lllp purchased a new position in shares of Labcorp in the 2nd quarter worth approximately $58,000. Institutional investors own 95.94% of the company’s stock.

Trending Headlines about Labcorp

Here are the key news stories impacting Labcorp this week:

• Positive Sentiment: Labcorp reported third-quarter adjusted earnings of $4.78 per share, above the $4.64 consensus estimate, while revenue increased 6.9% year over year to $3.81 billion, topping expectations. The company also raised its outlook, supporting the investment case. Labcorp Q3 2026 Earnings Call Highlights
• Positive Sentiment: Truist raised its price target to $395 from $365 and maintained a Buy rating, while Robert W. Baird increased its target to $396 from $361 and retained an Outperform rating. The revisions indicate analysts see additional upside after the earnings beat. Truist Raises Labcorp Price Target
• Positive Sentiment: Zacks identified LH as a highly ranked value stock, potentially attracting investors seeking a combination of earnings strength and reasonable valuation characteristics. Labcorp Is a Top-Ranked Value Stock
• Neutral Sentiment: Labcorp’s estimated fair value moved modestly higher following third-quarter analyst revisions, suggesting improving expectations but limited near-term valuation support. Labcorp Fair Value Edges Higher
• Negative Sentiment: Analysts continue to flag potential pressure from changes to Medicare laboratory reimbursement rules under PAMA. That risk may temper the benefit of better earnings and guidance. Labcorp Stock Shrugs Off Q3 Earnings as PAMA Risk Looms
• Negative Sentiment: A Seeking Alpha contributor downgraded the stock, arguing that investor optimism and the sharp advance toward a 52-week high may have outpaced Labcorp’s underlying upside. Deutsche Bank raised its target to $355 but maintained a Hold rating, reinforcing valuation concerns. Labcorp Rating Downgrade

About Labcorp

Labcorp (NYSE: LH), formally Laboratory Corporation of America Holdings, is a global life sciences and healthcare company headquartered in Burlington, North Carolina. The company provides laboratory testing and diagnostic services to physicians, hospitals, health systems, employers, insurers and consumers.

Through its diagnostics operations, Labcorp offers routine and specialty testing, oncology diagnostics, women’s health testing, genetic testing, pathology services and other laboratory services.